MNK Stock Mallinckrodt plc - Complete Overview

Nyse / Pharmaceutical Products / Healthcare / MNK Stock

Mallinckrodt plc (MNK) price per share as of 20 Apr 2018
USD
Your sentiment
COLDTRENDOMETERHOT
Shares Outstanding 86.35M
Avg Daily Volume 3.99M
Market Cap 1.61B
Volatility 58.57% MEDIUM

MALLINCKRODT PLC (MNK) OVERVIEW

MNK stock is a pharmaceutical products company traded on Nyse. It is valued at 1.61B US dollars. There are 86.35M shares outstanding which Mallinckrodt plc issued to investors. Volatility of the stock is MEDIUM, and the daily volume is 58.57% stock on average. It brought investors a total return of -68.38% over the last 12 months. Mallinckrodt plc stock is relatively cheap. It's P/E ratio is below the market average.

Mallinckrodt plc (MNK) STOCK PRICE PERFORMANCE

MNK SHAREHOLDER'S RETURN

Earnings Per Share 21.85
Dividends Per Share 0.00
12 Months Price Performance Negative
Total Return Negative

MNK LATEST NEWS

Mallinckrodt: Are Bondholders Predicting Impending Doom?

MNK's bonds due April 2023 yield over 12%, implying the credit markets could be closed to the company. I doubt MNK will be able to generate the $3B in cash flow needed to make principal payments due b

Are The Shorts Right About Mallinckrodt?

Shorts are repeating the same thesis over and over.Debt remains manageable, bankruptcy remains a remote possibility.Recent allegations are a repetition of past thesis advocated by shorts which are lik

Whistleblower Claims Mallinckrodt Is Scheming To Spike Acthar Sales

A whistleblower claims no one knows exactly what is in MNK's top-selling Acthar.The drug is indicated to treat multiple sclerosis and infantile spasms.The lawsuit could prompt insurers and/or the gove

3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey

Fate Therapeutics shows early promise in ovarian cancer.Mallinckrodt on deck for its hyperbilirubinemia drug.Insmed demands its day with the FDA.

President Trump Considers Suing Opioid Manufacturers

President Trump intimated he was considering suing drug makers for their role in the opioid epidemic.I believe MNK, ENDP and INSY are particularly vulnerable.Avoid all three stocks.

Depomed Distances Itself From Nucynta

DEPO is distancing itself from Nucynta, which represented over 60% of past sales.It now has an uncertain business model that may or may not work.It has over $600MM of debt at junk levels.A high debt l

Mallinckrodt plc (MNK) TECHNICAL INDICATORS

Name Value Action
RSI(14) 38.59 Sell
CMO(14) -22.82 Sell
ADX(14) 20.99 N/A
Williams %R -78.85 Overbought

MNK STOCK VALUATION

MNK Industry Sector Market
Price to Earnings 0.85 67.64 84.09 30.67
Price to Book Value 0.25 3.93 4.63 3.52
Price to Sales 0.50 3.57 4.30 3.34
Return on Equity 39.10% 16.58% 22.79% 15.18%
Return on Assets 14.40% 4.83% 6.75% 5.64%
All values TTM (trailing twelve months). Source: Quandl.com

MNK FORUM DISCUSSIONS